EFFICACY AND SAFETY OF LOW-DOSE ORAL MINOXIDIL IN THE TREATMENT OF ANDROGENETIC ALOPECIA – A LITERATURE REVIEW
Authors:
- Filip KielochFKFilip Kieloch
- Agnieszka FitasAFAgnieszka Fitas
- Karol KanonKKKarol Kanon
- Mathias SpitaleriMSMathias Spitaleri
- Wiktor GąskaWGWiktor Gąska
- Oskar SienkielOSOskar Sienkiel
- Julia GłowackaJGJulia Głowacka
- Wojciech GąskaWGWojciech Gąska
- Dawid SewrukDSDawid Sewruk
- Karolina Dębek-KalinowskaKDKarolina Dębek-Kalinowska
Open Access
- 8 September 2025
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(47))
Abstract
Introduction: Androgenetic alopecia (AGA) is a chronic progressive form of hair loss affecting a significant portion of the adult population. Although topical minoxidil has a proven efficacy, it is often associated with low adherence due to adverse effects and the inconvenience of use. Increasing attention is being paid to low-dose oral minoxidil (LDOM), which may represent a therapeutic alternative with a favorable safety profile. Purpose of The Work: The aim of this study was to assess the efficacy and safety of low-dose oral minoxidil (≤5 mg/day) in the treatment of androgenetic alopecia based on current clinical trial data. Material and Methods: A narrative literature review was conducted, including studies published in English between 2019 and 2024, concerning the efficacy and safety in patients with AGA. A total of 9 publications meeting the inclusion criteria were analyzed. Results: The analyzed studies demonstrated that LDOM increases both the number and diameter of hair in patients – in both men and women. The best results were observed at doses of 1-5 mg/day, although even very low doses (0.25 mg/day) yielded measurable effects. Adverse events were generally mild – most commonly hypertrichosis and cardiovascular symptoms (e.g., tachycardia), with incidence increasing with dose. Serious complications were rare and occurred primarily in patients with pre-existing heart disease. Conclusion: Low-dose oral minoxidil is an effective and well-tolerated treatment option for AGA. Further studies are needed to standarize dosing and assess the long-term safety of the therapy.Keywords
This publication has 33 references indexed in Scilit:
- Oral Minoxidil vs Topical Minoxidil for Male Androgenetic AlopeciaJAMA Dermatology, 2024
- Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair loss: 0.25 mg versus 1 mgJournal of the American Academy of Dermatology, 2022
- Hair transplantation: Basic overviewJournal of the American Academy of Dermatology, 2021
- Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic AssessmentDermatology and Therapy, 2020
- Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentationJournal of the American Academy of Dermatology, 2020
- Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trialJournal of the American Academy of Dermatology, 2020
- Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopeciaJournal of the American Academy of Dermatology, 2019
- Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicleJournal of Dermatological Science, 2004
- Androgenetic alopecia: pathogenesis and potential for therapyExpert Reviews in Molecular Medicine, 2002
- Finasteride in the treatment of men with androgenetic alopeciaJournal of the American Academy of Dermatology, 1998